NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group